Although VEGFR-3 deficiency disrupts blood vascular development during early embryogenesis, the underlying mechanism was not clear. To characterize its function in angiogenesis and lymphangiogenesis, we employed two genetically modified mouse models in this study, targeting the coding region for the ligand-binding domain (Vegfr3 ∆LBD ) or the tyrosine kinase domain with an inactivation point mutation (Vegfr3 TKmut ). We show that lymphatic growth was disrupted in Vegfr3 ∆LBD/∆LBD and Vegfr3 TKmut/TKmut mice, but blood vessels developed normally in both embryo and yolk sac. Interestingly, in Vegfr3 ∆LBD/∆LBD but not Vegfr3 TKmut/TKmut mice, lymph sac was present but there was lack of lymphangiogenic sprouting. We further demonstrate that both the wild-type and mutant forms of VEGFR-3 could form heterodimers with VEGFR-2, and decreased the level of phospho-VEGFR-2 and the downstream phospho-Erk1/2 in endothelial cells when they were treated with VEGF-A. These findings indicate that signaling mediated via VEGFR-3 activation by its cognate ligands (VEGF-C/-D) is not required for angiogenesis, and that VEGFR-3 may play a role in this process by modulating VEGFR-2-mediated signals.
Introduction
The formation of blood vascular system during embryonic development is a strictly regulated process, with the first formation of primary vascular plexus from the endothelial precursors present in the blood islands of developing embryos, followed by further remodeling into a mature vascular network with a hierarchy of vessels [1] [2] [3] . Lymphatic vessel development occurs later than blood vasculature, and initiates by the process of polarized endothelial cell (EC) budding from the cardinal vein after a subpopulation of blood vascular ECs differentiate into lymphatic ECs (LECs) expressing Sox18 and Prox1 [1, [4] [5] [6] . Various factors have been shown to play a role in the development of blood vascular and lymphatic systems. Among them are vascular endothelial growth factors (VEGFs) including five members identified to date in mammals, VEGF, VEGF-B, VEGF-C, VEGF-D, and placenta growth factor. These factors have distinct roles in vascular development by activating their respective receptors known as VEGF receptor-1, -2, and -3 as well as co-receptors such as heparan sulfate proteoglycans (HSPGs) and neuropilins [1, 7, 8] . VEGF is a key growth factor for blood vessel formation via VEGFR-2, and VEGF-C/-D activate primarily VEGFR-3. After the proteolytic processing, both VEGF-C/-D have shown increased affinities for VEGFR-3, and the fully processed mature forms also bind to and activate VEGFR-2 [9, 10] .
The VEGFR-2-mediated signaling pathway plays essential roles in vascular development, including EC proliferation, migration, survival, and arterial-venous specification by the differential regulation of the downstream target activation [7, 8, 11] . VEGFR-3-mediated signals are required for lymphatic vessel growth in development and tumor [12] [13] [14] . During the murine development, VEGFR-3 is initially expressed by all the ECs of primary vascular network. While VEGFR-3 is expressed mainly in LECs at later stage of embryogenesis and persists in adult lymphatic vessels [15] , it could be induced in blood vessels undergoing active angiogenic sprouting, and in some tumor-associated blood vessels [16] [17] [18] [19] . The requirement of VEGFR-3 for blood vascular development was first shown by genetic studies showing that mice null for VEGFR-3 die at midgestation (E10.5) before the emergence of lymphatic vessels, resulting from the failure of the remodeling of primary vascular network into a hierarchy of vessels [20, 21] . However, deletion of VEGF-C, or both VEGF-C/-D, disrupted only lymphatic growth but did not affect blood vascular development [22] . The underlying mechanism for the distinct phenotypes between the mice deficient for VEGFR-3 or its ligands was not clearly understood.
To investigate the biological function of VEGFR-3 in angiogenesis and lymphangiogenesis, we generated a conditional knockout model targeting its ligand-binding domain (LBD) in this study. Mice homozygous for the LBD deletion (Vegfr3 ∆LBD/∆LBD ) showed only disruption of lymphatic growth, but blood vascular development in both embryo and yolk sac was not affected. Consistently, using an independent mutant mouse model in which the kinase activity of VEGFR-3 is ablated by a missense mutation in the tyrosine kinase catalytic domain, we have further validated that signaling mediated via the activation of VEGFR3 kinase is only crucial to lymphangiogenesis, but not required for blood vascular development.
Results

Generation of mice expressing VEGFR-3 ∆LBD
In this study, we have generated Vegfr3
Flox mice targeting its LBD, including Ig-like domain 2 and part of Ig-like domain 3 encoded by exon 4-6 of Vegfr3 gene (Supplementary information, Figure S1A ). To verify that the conditional allele was functional, Vegfr3
Flox mice were crossed with EIIA-Cre mice [23] . Germ-line deletion of the floxed region of Vegfr3 gene was confirmed by expression analysis of embryos (E10.5) at the mRNA and protein level ( Figure 1A and 1B) . As shown in Figure 1A , RT-PCR for VEGFR-3 produced two bands with different sizes in the homozygous Vegfr3 ∆LBD/∆LBD mice. The bands were further analyzed by DNA sequencing, and the upper band corresponded to the predicted form of VEGFR-3 mRNA missing exon 4-6 coding sequence, which may encode a truncated protein, if any, by exon 1-3 plus part of exon 7 due to a frame shift to introduce a stop codon. Interestingly, the extra lower band resulted from an alternative splicing of VEGFR-3 pre-mRNA missing exon 4-7 coding sequence, which encoded a novel form of VEGFR-3 lacking only the extracellular Ig-like domains 2 and 3 (aa 134-328) corresponding to the speculated ligand-binding region (named VEGFR-3 ∆LBD ). Expression of VEGFR-3 ∆LBD protein was confirmed by western blot analysis ( Figure 1B) . We further showed that VEGFR-3 ∆LBD did not have VEGF-C binding activity by co-expressing VEGF-C and VEGFR-3-Ig ∆LBD (comprised of the full extracellular domains of VEGFR-3 lacking Ig-like domains 2 and 3, and fused with human IgG Fc) in 293E cells. VEGFR-3-Ig consisting of the full extracellular domains plus IgG1 Fc was used as a control ( Figure 1C ).
Blood vascular network forms normally in mice expressing VEGFR-3 ∆LBD
To our surprise, we found that mice homozygous for deletion of the LBD (Vegfr3 ∆LBD/∆LBD ) developed normally at E10.5 ( Figure 1D ), which was different from the VEGFR-3-deficient mice displaying embryonic lethality at the same stage [20] . There were no obvious defects with the formation of the blood vascular network in both the embryo (head region, Figure 1D ; somite region, Supplementary information, Figure 1B ) and yolk sac ( Figure 1E ). Immunofluorescence staining for PECAM-1 and VEGFR-3 further demonstrated that VEGFR-3 or VEGFR-3 ∆LBD was expressed by blood vessels in embryos and yolk sac at E10.5 ( Figure 1D and 1E), with high expression in the central veins and blood capillaries but low in the intracranial arteries ( Figure 1D , white arrow). The intracranial arteries displayed relatively stronger staining for PECAM-1 ( Figure 1D , arrow), but were not stained by EphB4, a vein marker, which mainly stained the central vein region (data not shown). VEGFR-3 expression persisted in the yolk sac blood vessels, but was downregulated in those of embryos with only weak staining in blood capillaries by E15.5 (Supplementary information, Figure S2A and S2B). In addition, we found that LYVE1, originally identified as a lymphatic marker [24] , was also highly expressed by blood vessels in yolk sac ( Figure 1E and Supplementary information, Figure S2B ), consistent with the observation by Gordon et al. [25] .
We further examined the vascular development in Vegfr3 ∆LBD/∆LBD mice at E15.5. As shown in Figure 2A , Vegfr3 ∆LBD/∆LBD mice developed severe edema (arrowhead). Whole-mount immunostaining of the skin showed that there was no lymphatic vessel formation in the mice expressing VEGFR-3
∆LBD
, but blood vascular network formation was not affected (Figure 2A , arrows). Figure S3 ) and is also weakly detectable in HUVECs (data not shown), while there was no detectable phosphorylation of the kinase inactive form of VEGFR-3 resulting from a point mutation in its kinase region (I1053F, VEGFR-3 TKmut , Supplementary information, Figure S3 ) [26] . In addition, VEGFR-3 has been shown to interact with other vascular regulators, including integrin β1 [27] , neuropilin-2 (NRP2, a co-receptor of VEGFR-3) [28] , and VEGFR-2 [29] . This suggests that activation of VEGFR-3 kinase can occur in a VEGF-C/-D-independent manner, which may account for the LS formation in Vegfr3 ∆LBD/∆LBD mice.
Lymph sac (LS) forms
Blood vessels develop normally in mice lacking VEG-FR-3 kinase activity
To further investigate the biological function of VEGFR-3 in blood vascular development, we used another independent mouse model in which the tyrosine kinase activity was impaired due to the point mutation as described above (VEGFR-3 ∆LBD/∆LBD mice showed edema due to lack of lymphatic network formation. (A) Visualization of blood vessels (arrows) and lymphatics in the dorsal skin (dotted white square) by whole-mount immunostaining for PECAM-1 (green) and LYVE-1 (red) in Vegfr3 ∆LBD/∆LBD embryos (E15.5). Note that there is no lymphatic vessel detected in mice homozygous for the LBD deletion and mice show subcutaneous edema (arrowhead). Scale bars, 200 µm. (B) Sections across E13.5 embryo jugular areas were stained for PECAM-1 (red) and LYVE-1 (green). Jugular lymph sacs (LS) were detected in Vegfr3 ∆LBD/∆LBD embryos, but with a round shape, which is different from that of WT and heterozygous mice undergoing active lymphatic sprouting (arrows). A, dorsal aorta; V, jugular vein. Scale bars, 100 µm. TKmut/TKmut embryos appeared normal at E10.5. There was no obvious abnormality observed with blood vasculature in yolk sacs stained for PECAM-1 (red). Whole-mount staining with embryos also showed normal vascular development (PECAM-1, green; VEGFR-3, red). Arrowhead indicates intracranial arteries. Scale bars, 300 µm. Figure 3A and 3B. Western blot analysis revealed that the expression level of VEGFR-3
TKmut is similar to that of WT mice ( Figure 3C ). Interestingly, mice homozygous for the mutation (Vegfr3 TKmut/TKmut ) appeared normal when examined at E10.5 ( Figure 3D ). Immunohistochemical analysis for PECAM-1 and VEGFR-3 revealed that blood vessels formed in yolk sac, head and somite region in Vegfr3
TKmut/TKmut mice, which is comparable to that in WT embryos ( Figure 3D and Supplementary information, Figure S4 ).
We further examined vascular development in Vegfr3
TKmut/TKmut embryos at E15.5. As shown in Figure 4A , severe edema was observed in all the mice homozygous for the tyrosine kinase mutation, and was also seen in approximately half of the heterozygous mice (Vegfr3 and WT mice, tumor grew at a similar rate and there was no obvious difference in tumor-associated angiogenesis (Supplementary information, Figure S5D ). These results are consistent with the vascular phenotype of Vegfr3 ∆LBD/∆LBD mice, and further validates that signaling mediated via the activation of VEGFR-3 kinase is not required for blood vessel growth.
As expected, there was no lymphatic vessel growth observed in Vegfr3
TKmut/TKmut mice ( Figure 4A ). In the WT/TKmut embryos also showed similar phenotype (arrowhead). The dorsal skin (dotted square) was stained for PE-CAM-1 (green) and LYVE-1 (red). Blood vessels (arrows) developed normally while there were no lymphatic vessels detected in the skin of homozygous mutant mice and very few detected in that of heterozygous mice. Scale bars, 300 µm. (B) E13.5 embryo sections across the jugular region were stained for PECAM-1 (red) and LYVE-1 (green), and jugular lymph sacs (LS) were observed in Vegfr3 WT ) could interact and be coprecipitated with VEGFR-2. (B) HUVECs were transduced with the recombinant adenoviruses overexpressing the three different forms of VEGFR-3, and then stimulated with VEGF 165 as described in Materials and Methods. An equal amount of protein was subjected to western blot analysis for the total and phosphorylated VEGFR-2. (C) The same samples (used in B) were also analyzed for total ERK1/2 and phospho-ERK1/2. IP: immuno-precipitation; WB: western blot; TCL: total cell lysate; Ctrl: control; R2: VEGFR-2; R3: VEGFR-3; arrows point to VEGFR-3 or VEGFR-2 protein; dotted arrows point to the ligand-binding domain-deleted VEGFR-3 (VEGFR-3 ∆LBD ).
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heterozygous Vegfr3 WT/TKmut mice, there was also no lymphatic vessel growth toward the dorsal central line ( Figure  4A ), while few enlarged lymphatic vessels around the forelimb skin were occasionally seen (data not shown). There was also no LS formation observed in Vegfr3 TKmut/ TKmut mice at E13.5 ( Figure 4D ). However, LS formation could be observed in the heterozygous Vegfr3 WT/TKmut mice ( Figure 4B ), in spite of the decrease in VEGFR-3-mediated signals due to the dominant-negative effect of VEG-FR-3
TKmut . This indicates that the remaining VEGFR-3 signals are sufficient for the primary LS formation, but insufficient for subsequent lymphangiogenesis, leading to the abnormal development of lymphatic system in the heterozygous Vegfr3
WT/TKmut mice (our unpublished data).
VEGFR-3 regulates VEGFR-2-mediated signaling
To understand the underlying mechanism of the requirement of VEGFR-3 in vascular development, we generated constructs encoding the ligand-binding domain (LBD) deleted (VEGFR-3 ∆LBD ), kinase mutated (VEG-FR-3
TKmut
) and WT VEGFR-3, respectively. As shown in Figure 5A , all three forms of VEGFR-3 can interact and be co-precipitated with VEGFR-2 when they were coexpressed in 293T cells. This interaction has also been confirmed in HUVECs (data not shown).
To further investigate the consequence of VEGFR-2 and VEGFR-3 interaction, we transduced HUVECs with adenoviral vectors overexpressing each of the three forms of VEGFR-3, and cells were then stimulated with VEGF 165 recombinant protein for the analysis of the phosphorylated VEGFR-2 level. Shown in Figure 5B is the representative image of five independent experiments. We consistently observed that the phosphorylated VEGFR-2 level was decreased after the overexpression of either the mutant or WT VEGFR-3. This was further confirmed by analysis of the downstream signal mediator, phospho-ERK1/2, which was also decreased as shown in Figure 5C . The findings suggest that VEGFR-3 can modulate EC response to VEGF-A via interaction with VEGFR-2, and that this can be in a ligand-binding or kinase activity-independent way.
The vascular phenotypes of the three genetically engineered mice for VEGFR-3 are summarized in Figure 6A . The potential mechanism of VEGFR-3 function in LS formation and blood vascular growth is proposed in Figure 6B and 6C, and a detailed account has been provided in the figure legend.
Discussion
In this study, we have analyzed the role of VEGFR-3 in angiogenesis and lymphangiogenesis using geneti- cally modified mouse models targeting its LBD or kinase activity. We show that both mutant forms of VEGFR-3 (VEGFR-3 ∆LBD and VEGFR-3 TKmut ) can rescue the blood vascular defects observed in VEGFR-3 null mice [20, 21] , but lymphangiogenesis is disrupted in both mutant mice. Interestingly, we have observed that LS formation occurs in mice when the LBD of VEGFR-3 is deleted, TK TK  TK TK  TK TK  TK TK  TK TK  TK TK  TK TK   TK TK  TK TK  TK TK  TK TK  TK TK  TK TK  TK  TK   TK [12] and in tumor experiments [14, 31] , where the soluble VEGFR-3-Ig fusion protein could efficiently block developmental or tumor-associated lymphangiogenesis, but not angiogenesis, by trapping its cognate ligands. Consistently, we have further shown that the blood vascular network also appears normal in mice when the tyrosine kinase activity of VEGFR-3 is ablated. This further validates the above conclusion that signals mediated via VEGFR-3 kinase activation are dispensable for blood vessel growth. Evidence from extensive studies have shown that the VEGFR-2-mediated signaling pathway plays a crucial role in the regulation of blood vascular network formation, and its activation is strictly regulated at both the ligand and receptor levels [7, 8] . It has been shown that VEGFR-1 negatively regulates VEGFR-2 signaling by sequestering its ligand VEGF [32] . Findings from this study suggest another novel mechanism underlying the regulation of vascular network formation by VEGFR-3, which is independent of its ligand-binding or tyrosine kinase activity when expressed in blood vascular ECs during early embryogenesis. It has been shown that VEGFR-3 can form heterodimers with VEGFR-2 when co-expressed [33] , and such VEGFR-2/VEGFR-3 heterodimers could also be detected in vascular ECs in the EB (embryoid body) model by proximity ligation assay [29] . In this study, we have further shown that all the three forms of VEGFR-3 (VEGFR-3 WT , VEGFR-3 ∆LBD and VEGFR-3 TKmut ) could form heterodimers with 
lymphangiogenesis (indicated in the table as -). (B) Lymph sac (LS) formation. LS formation requires VEGFR-3 kinase activity, but is independent of the direct activation of VEGFR-3 by its cognate ligands (VEGF-C/-D). During embryogenesis (around E10 in mouse), a population of blood vascular endothelial cells (BECs) in the cardinal vein (CV) differentiate into lymphatic endothelial cells (LECs). Then LECs dissociate from
BECs and form a lymph sac adjacent to the cardinal vein. We have found that VEGFR-3 kinase activity is essential for lymph sac formation as LS does not occur in mice with a kinase-inactive VEGFR-3 (Vegfr3
TKmut/TKmut
). However, lymph sac formation occurs in the absence of ligand-binding activity of VEGFR-3 as shown in Vegfr3 ∆LBD/∆LBD mice. It is possible that VEGFR-3 ∆LBD undergoes the ligand-independent autophosphorylation as shown in Supplementary information, Figure S3 . It is also likely that the VEGFR-3 interacting factors, including neuropilin-2 (NRP2, a co-receptor of VEGFR-3), integrin β1 or VEGFR-2, could form complexes with VEGFR-3 ∆LBD and activate its kinase activity for downstream signaling. The exact mechanism of lymph sac formation in Vegfr3 ∆LBD/∆LBD mice remains to be investigated. (C) Blood vascular development is independent of VEGFR-3 ligand binding and kinase activity. Shown in this panel is the schematic illustration of the interactions and potential roles of VEGFR-1, VEGFR-2 and VEGFR-3 in the regulation of angiogenesis. VEGFR-1 has been shown to negatively regulate VEGFR-2 signaling by sequestering its ligand VEGF-A. Based on our findings from two genetically modified models, we conclude that VEGFR-3 ligand binding and kinase activity are not required for angiogenesis. At least in cultured endothelial cells (HUVECs), we have found that VEGFR-3 can form heterodimers with VEGFR-2 and regulate its phosphorylation level upon VEGF-A treatment. Therefore, it is possible that VEGFR-3 plays a role in the regulation of blood vessel growth by modulating VEGFR-2-mediated signals. In addition, as VEGFR-3 can interact with other factors as described above, it is also possible that VEGFR-3 could be activated in a way different from that induced by its cognate ligands, and participates in the regulation of blood vascular development. Further studies are required to elucidate the precise mechanism underlying the role of VEGFR-3 in vascular growth.
but this does not happen in mice when the tyrosine kinase activity of VEGFR-3 is ablated. We further demonstrate that the mutant or WT forms of VEGFR-3 can form heterodimers with VEGFR-2 and regulate its phosphorylation level in HUVECs upon VEGF-A treatment. Based on these findings, we conclude that VEGFR-3 activation by its cognate ligands (VEGF-C/-D) is only crucial to lymphangiogenesis but not required for angiogenesis, and propose that VEGFR-3 may play a role in blood vascular development by modulating VEGFR-2-mediated signals.
We have found that VEGFR-3 is widely expressed in blood vessels with high expression in blood capillaries and veins but low in arteries during early embryonic development. However, it is not clear whether VEGFR-3 expressed by blood vascular ECs transduces any signals for angiogenesis. Mice deficient of VEGF-C or both VEGF-C/-D appeared normal at E10.5 and did not show any obvious blood vascular defects observed in VEGFR-3 deficient mice [22, 30] . This suggests that the VEGF-C(-D)/VEGFR-3 signaling pathway is not required for blood vascular development. Results obtained from our newly generated genetic model (Vegfr3 VEGFR-2 in a ligand-independent manner in cultured cells. Overexpression of either the WT or mutant forms of VEGFR-3 could decrease the level of phosphorylated VEGFR-2 in HUVECs when treated with VEGF-A. This was also validated by the reduced level of its downstream mediator phospho-Erk1/2 in the same cells. These findings suggest that VEGFR-3 exerts its required function in vascular development indirectly by regulating the level of VEGFR-2 activation, providing an additional layer of control over VEGFR-2-mediated signals. However, it is also possible that VEGFR-3 may function in angiogenesis via interaction with other vascular modulators such as integrin β1 [34, 35] , as proposed in Figure 6 . Further in vivo studies are required to verify this. While it has been reported that VEGFR-3 blocking antibodies could suppress angiogenesis in tumor and normal tissues [19] , it is likely that the observed angiogenic blocking effects may be due to the interference with VEGFR-2 or other factor-mediated signals in blood vascular ECs.
Finally, interesting observations have also been made regarding VEGFR-3 in lymphatic development. We have confirmed that the extracellular Ig-like domains 2 and 3 of VEGFR-3 are crucial for its ligand-binding and lymphatic development, based on the analysis of Vegfr3 ∆LBD/∆LBD mice. Deletion of the LBD of VEGFR-3 disrupted lymphangiogenesis, but LS formation occurred in these mice. There is no LS formation and lymphatic vessel growth observed in Vegfr3
TKmut/TKmut mice. This suggests that the kinase of VEGFR-3 ∆LBD can still be activated and transduces signals for LEC proliferation and survival after their differentiation from blood vascular ECs, although there is no lymphatic sprouting due to the loss of ligand-sensing ability by LEC expressing VEGFR-3
∆LBD
. It is likely that LS formation is independent of the direct activation of VEGFR-3 by its cognate ligands (VEGF-C/-D), and that VEGFR-3 ligands may be required later to provide the spatial cue for lymphatic sprouting from the LS. The exact mechanism of VEGFR-3 ∆LBD activation remains to be investigated. It is possible that VEGFR-3 ∆LBD undergoes the ligand-independent autophosphorylation as shown in Supplementary information, Figure S3 . It is also likely that other VEGFR-3 interacting factors, including NRP2 [28, 36] , integrin β1 [27] , or VEGFR-2 [29] , could form complexes with VEGFR-3 ∆LBD and activate its kinase activity for downstream signaling. However, we have not been able to detect any phospho-VEGFR-3 ∆LBD in embryonic tissues, which may also be due to the fact that the proportion of LECs is small at the stage of LS formation. Therefore, it becomes necessary to isolate the primary LECs expressing VEGFR-3 ∆LBD for further analysis. To summarize, in this study we have successfully generated a mouse model expressing the ligand-binding domain deleted form of VEGFR-3. In combination with another genetic model expressing a kinase inactive form of VEGFR-3, we have shown that the VEGFR-3 ligand binding/kinase activation-mediated signaling pathway is required for lymphangiogenesis but not for angiogenesis. Regulation of vascular development requires a finely coordinated molecular network with dynamic expression/ activation meeting the various cellular needs. In addition to the advanced molecular and cellular tools, more carefully designed genetic models targeting the functional domains or protein interacting sites of vascular regulators are particularly needed to help provide novel insights into the molecular mechanisms underlying blood vascular development.
Materials and Methods
Generation of Vegfr3
Flox mice and animal work
All animal experiments were performed in accordance with the institutional guidelines of Model Animal Research Center, Nanjing University. For construction of the Vegfr3
Flox allele, we used the standard BAC retrieval method [37] . Briefly, a 9.6-kb DNA fragment containing the targeting region was retrieved from BAC: BMQ433M21. The first loxP was inserted into intron 3, and the second loxP together with neomycin-resistant gene flanked by FRT sites was inserted into intron 6. The construct was linearized by NotI and electroporated into R1 embryonic stem cells [38] . Positive ES cell clones were identified by PCR and chimeric mice were generated by microinjection of the ES cells into blastocysts of B6 strain. Genetic transmission was confirmed by backcrossing the chimera with C57BL/6J mice and the Neo-cassette was removed using FLPeR mice as previously described [39] .
To examine the floxed allele, Vegfr3 Flox mice were crossed with EIIA-Cre mice [23] to remove the genomic DNA between the two loxP sites including exon 4-6 of Vegfr3, which were genotyped by PCR using primers as follows: forward primer (5′-AGA GAC TTC CTG AGC TGT TTC C-3′) and reverse primer (5′-AAG CAC AAG TGG TTC TGG GTG C-3′) to amplify a 900-bp fragment for the wild-type (WT) allele and a 227-bp fragment for the knockout allele.
Vegfr3 WT/TKmut mice were imported from the Medical Research Council Mammalian Genetics Unit Embryo Bank (Harwell, UK), which was generated by ENU (ethylnitrosourea) mutagenesis.
Vegfr3
WT/TKmut (also named Chy mice) [26] contains a point mutation (I1053F) in the tyrosine kinase region, which inactivates its kinase activity. Vegfr3
WT/TKmut mice were maintained in C3H background. As the point mutation ablated a BglII restriction site (from AGATCT to AGTTCT), genotyping was performed by amplifying a 495-bp DNA fragment containing the mutation site and then digested by BglII. Primers used are as follows: forward primer: 5′-TCC CAT TTT GGA GGA AAC TCA GC-3′; reverse primer: 5′-CAA AGG TTC CTG TCA CCT TGA GC-3′. PCR products were digested by BglII, which produced two bands (324 and 171 bp) with WT mice, while a 495-bp band was obtained from the Vegfr3
TKmut/TKmut mice. 
Immunostaining
For whole-mount immunostaining, embryos, yolk sac, embryonic back skin and postnatal retina were harvested, fixed in 4% paraformaldehyde, blocked with 3% (w/v) milk in PBS-TX (0.3% Triton X-100), and incubated with primary antibodies overnight at 4 °C. The antibodies used were rat anti-mouse PECAM-1 (BD Pharmingen, 553370) or hamster anti-mouse PECAM-1 monoclonal antibody (Chemicon, MAB1398Z), rabbit anti-mouse LYVE1 (Abcam, ab14917), affinity-purified goat anti-mouse VEGFR-3 (R&D Systems, AF743), and goat anti-mouse EphB4 (R&D Systems, AF446). Appropriate Alexa 488, Alexa594 (Invitrogen), Cy3 or Cy5 (Jackson) conjugated secondary antibodies were used for staining. All fluorescently labeled samples were mounted with Vectashield (VectorLabs), and analyzed with a confocal microscope (Leica TCS SP2 or Olympus FluoView 1000), or Leica MZ16F fluorescent dissection microscope.
For section staining, mouse embryos were collected and fixed in 4% PFA overnight at 4 °C, dehydrated and embedded in paraffin. Consecutive sections (6 µm) were incubated with antibodies for PECAM-1 (BD Pharmingen) or LYVE-1 (Abcam), followed by staining with the appropriate fluorochrome-conjugated secondary antibodies and mounted as described above.
Analysis of the alternatively spliced VEGFR-3 forms by RT-PCR
Embryos (E10.5) were collected and homogenized in Trizol (Invitrogen). RNA extraction and reverse transcription was performed following standard procedures. For PCR amplification of the cDNA fragment coding for the extracellular region of VEG-FR-3, the following primers were used: forward primer: 5′-ATC GAA GCT TTC ACT CCC AGC CTA GAG CTG C-3′; reverse primer: 5′-TAC CAG CGC AGA TGT TCG TAC G-3′. PCR products were gel purified, subcloned and followed by DNA sequencing.
DNA constructs
The full-length VEGFR-3 cDNA was obtained by RT-PCR from the liver tissue of C57BL/6J mice. Briefly two pairs of primers were used for the PCR amplification as follows: For1: 5′-ATC GAA GCT TGA GCT GCG GCC GCG CAG GTC-3′; Rev1: 5′-TAC CAG CGC AGA TGT TCG TAC G-3′; and For2: 5′-AAA GTG GGC CAG GAT GAG AGA C-3′; Rev2: 5′-AGC TGA TAT CTC CAC AGA CAA TCA GAT CCA GG-3′. The PCR fragments were subcloned into pcDNA3.1-V5-HisA vector (Invitrogen) to obtain pcDNA3.1-V5-HisA-mVEGFR-3, and the insert was verified by DNA sequencing. To generate the kinase inactive form of VEGFR-3 (VEGFR-3 TKmut ), we point-mutated the WT VEG-FR-3 cDNA following the procedures described in Stratagene's QuikChange® II Site-Directed Mutagenesis method. The primers used were as follows: A3157T-For: 5′-GAA AGT GAC ATA GTG AAG TTC TGC GAC TTT GGC CTC-3′ and A3157T-Rev: 5′-GAG GCC AAA GTC GCA GAA CTT CAC TAT GTC ACT TTC-3′. For the generation of LBD-deleted form of VEGFR-3, Vegfr3 ∆LBD/∆LBD embryos were collected for RT-PCR amplification of the cDNA fragment encoding the extracellular domain of VEGFR-3 lacking LBD, which was then ligated with the cDNA for the rest part of VEGFR-3 to obtain pcDNA3.1-V5-HisAmVEGFR-3 ∆LBD . The insert was verified by DNA sequencing. For the production of recombinant adenoviruses, all three forms of VEGFR-3 (WT, Tkmut and ∆LBD) were subcloned into pShuttle-IRES-hrGFP1 (Stratagene).
The full-length VEGFR-2 cDNA (NM_010612.2) was cloned from the mouse tissues as described above using the following primers: mKDR-For1: 5′-GCG GCC GCC ACC ATG GAG AGC AAG GCG CTG CTA GC-3′ and mKDR-Rev1: 5′-CTC ATC CAA GGG CAA TTC ATC TG-3′ to produce a 5′ 2.4-kb fragment, and mKDR-For2: 5′-GGG AAC TGA AGA CAG GCT ACT TGT C-3′ and mKDR-Rev2: 5′-CTC GAG AAC AGG AGG TGA GCG CAG TGT GG-3′ to produce a 3′ 1.6-kb fragment. The two fragments were ligated and subcloned into pcDNA3.1-V5-HisA and pShuttle-IRES-hrGFP1.
To generate soluble forms of VEGFR-3 fused with the human IgG1 Fc domain (VEGFR3-Ig WT and VEGFR3-Ig ∆LBD ), cDNA coding for the full extracellular domain of VEGFR-3 or lacking Ig-like domains 2 and 3 were PCR amplified from the respective constructs as described above. The primers used were as follows: mVEGFR3-For3: 5′-ATC GAA GCT TGA GCT GCG GCC GCG CAG GTC-3′ and mVEGFR3-Rev3: 5′-GTC AAG ATC TAC TGC CAC GCT GGC AGA G-3′. PCR products, together with the human IgG1 Fc coding region, were then subcloned into the pcDNA3 expression vector. The full-length human VEGF-C (NM_005429.2) was generated as previously described [40] and subcloned into pShuttle-IRES-hrGFP1 vector.
Cell culture
HUVECs were isolated from umbilical vein as previously described [41] , and cultured in Endothelial Cell Basal Medium plus supplements (Promocell). QBI-293A cells were propagated in DMEM (GIBCO) containing 4.5 g/l of glucose, 110 mg/l of Na pyruvate, 2 mM glutamine, penicillin (100 U/ml), streptomycin (100 µg/ml) and 10% FCS. 293T cells were cultured in DMEM with 10% FCS and 293E cells in DMEM with 5% FCS, in addition to the routine supplements. The murine Lewis lung carcinoma (LLC) cell line was obtained from American Type Culture Collection, and maintained in DMEM as specified by the manufacturer.
Adenovirus production
The recombinant adenoviruses expressing different forms of VEGFR- 3 (VEGFR-3   WT   , VEGFR-3 TKmut , and VEGFR-3 ∆LBD ) and GFP were generated using AdEasy system (Qbiogene, Inc.) following the manufacturer's instruction. Briefly, pShuttle-IREShrGFP1, pShuttle-VEGFR-3 WT -IRES-hrGFP1, pShuttle-VEGFR-3
TKmut -IRES-hrGFP1, pShuttle-VEGFR-3 ∆LBD -IRES-hrGFP1, and pShuttle-VEGFR-2-IRES-hrGFP1 were linearized by EcoRI or PmeI, and electroporated into BJ5183 containing pAdEasy1 adenovirus backbone vector. Recombined plasmids were further amplified using DH5α cells. Purified DNA was first linearized with PacI, and transfected into QBI-293A cells to produce the recombinant adenoviruses.
Transfection, immunoprecipitation, and western blot
For the study of VEGFR-2 and VEGFR-3 interaction, equal amounts of plasmid DNA were used for transfection of 293T cells using polyethylenimine (PEI, Linear, MW 25 000 Polysciences Inc. Cat #: 23966), and protein analysis was performed within 72 h. Briefly cells were washed with ice-cold PBS and lysed in 1 ml of the lysis buffer (2 mM PMSF, 2 mM Na 3 VO 4 , 0.5× Protease Inhibitor Cocktail Tablets without EDTA from Roche Applied Sci- ence, 20 mM Tris-HCl pH 8.0, 100 mM NaCl, 10% glycerol, 50 mM NaF, 10 mM β-glycerolphosphate, 5 mM sodium pyrophosphate, 5 mM EDTA, 0.5 mM EGTA, 1% NP-40). The cell lysates were incubated at 4 °C for 0.5 h with rotation and was clarified by centrifugation. Protein concentration was determined using BCA protein assay kit (PIERCE). Equal amounts of protein were used for analysis and VEGFR-2 was immunoprecipitated using rabbit polyclonal anti-VEGFR-2 antibodies [42] or M2 beads (Sigma A2220) for Flag-tagged VEGFR-2, and western blotted for VEG-FR-3 (eBioscience, AFL4).
For VEGF-C and VEGFR-3 binding experiment, 293E cells were transfected with plasmids expressing hVEGF-C plus VEG-FR3-Ig WT or plus VEGFR3-Ig ∆LBD . Cells were changed to serum free DMEM 1 day after transfection. The supernatant were collected 2 days later, and was analyzed by immunoprecipitation for VEGFR3-Ig using Protein A-Sepharose 4B (ZYMED 10-1141), followed by western blot for VEGF-C [43] .
For the analysis of VEGFR-2 phosphorylation, HUVECs were transduced with recombinant adenoviruses expressing the different forms of VEGFR-3 as described above. Cells were cultured for 2 days before starvation for 16 h, followed by stimulation with 50 ng/ml recombinant VEGF 165 (R&D, 293-VE) for 5 min at 37 °C. Cells were collected for protein analysis as described above. Antibodies used include mouse monoclonal to VEGFR-2 (A-3, SANTA CRUZ sc-6251); rat monoclonal to mVEGFR-3 (AFL4, eBioscience 14-5998); rabbit monoclonal to phospho-VEGFR-2 Tyr1175 (Cell Signaling Technology #2478); rabbit monoclonal to Erk1/2 (Cell Signaling Technology #9102); rabbit monoclonal to phosphoErk1/2 (Cell Signaling Technology #9101); and mouse monoclonal to β-actin antibody (C4, SANTA CRUZ sc-47778).
For the analysis of in vivo expression of VEGFR-3 WT , VEGFR-3
TKmut , and VEGFR-3 ∆LBD , E10.5 embryos were collected and homogenized in the lysis buffer as described. Equal amount of protein was used for analysis and VEGFR-3 was immunoprecipitated using goat polyclonal anti-mouse VEGFR-3 antibody (R&D Systems, AF743). The immunocomplexes were pulled down using Protein G-Sepharose 4B (Zymed, 101242), and analyzed by western blot using the monoclonal rat anti-mouse VEGFR-3 antibody (AFL4, eBioscience).
Xenotransplantation
Approximately 2.0 × 10 6 LLC cells in 100 µl of PBS were implanted in the s.c. tissue of the back flank region of WT and heterozygous Vegfr3 WT/TKmut mice (backcrossed into the C57BL/6JO1aHsd genetic background, 8-10 weeks old). The tumor-bearing mice were sacrificed within 3 weeks, and tissues were collected and processed for histological analysis.
Statistical analysis
Statistical analysis was performed with the unpaired t test. All statistical tests were two-tailed.
